Axovant Sciences (AXON): Allergan Acquisition of Chase a Positive - Baird
- Japan's Nikkei posts biggest point gain for fiscal year
- Citi downgrades tech stocks as its flagship indicator signals 'euphoria' levels
- UBS sees 5 warnings signals on semiconductor chip stocks
- 2 reasons why Tesla stock fell on Thursday
- US consumer sentiment tops estimates in March to hit nearly 3-yr high, UMich says
- AMC Entertainment (AMC) enters into an equity distribution agreement
- Kerrisdale Capital is short Microstrategy (MSTR), long bitcoin
- AMC Entertainment (AMC) Enters $250M ATM Agreement
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- Home Depot (HD) to Acquire SRS Distribution for $18.25B EV
Baird Sees Minimal Read Through for Axovant (AXON) on Lilly's Sola Failure
November 23, 2016 12:26 PM ESTBaird analyst Brian Skorney came out to defend Axovant Sciences (NYSE: AXON), which was weaker on Lilly's solanezumab failure. The analyst sees no change for AXON and maintained an Outperform rating and price target of $29.
Skorney commented, "The Alzheimer's field was... More
Axovant Sciences (AXON), vTv Therapeutics (VTVT) Mechanisms Don't Overlap with Sola - Piper
November 23, 2016 11:22 AM ESTPiper Jaffray analyst Charles Duncan said Lilly's solanezumab failure doesn't change their perception of risk for Axovant Sciences (NYSE: AXON) or vTv Therapeutics (NASDAQ: VTVT), noting these candidates have mechanisms that do not overlap with... More